The TARGET Neuroblastoma projects elucidate comprehensive molecular characterization to determine the genetic changes that drive the initiation and progression of high-risk or hard-to-treat childhood cancers.

Neuroblastoma (NBL) is a cancer that arises in immature nerve cells of the sympathetic nervous system, primarily affecting infants and children. It can have a devastating impact on patients and their families. Neuroblastoma accounts for ~12% of childhood cancer mortality; those between 18 months and 5 years of age are affected most severely. Furthermore, current NBL treatment involves harsh chemoradiotherapies that generally leave surviving children with lifelong side effects. The discovery of novel therapeutic targets in neuroblastoma could not only improve the outcomes of high-risk patients, but could also reduce the burden of sustained complications for surviving patients. To learn more about neuroblastoma and current treatment strategies, visit the NCI neuroblastoma website.

Last updated: September 02, 2020